The anticancer drugs /
Pratt, William B.
The anticancer drugs / William B. Pratt [and three others]. - Second edition. - New York : Oxford University Press, c1994 - viii, 352 pages : illustrations ; 26 cm.
Includes bibliographical references and index.
Principles of cancer chemotherapy -- Cancer problem -- Some milestones in the development of cancer chemotherapy -- Determinants of drug responsivveness -- Resistance to anticancer drugs -- Anticancer drugs -- Antimetabolites -- Folate antagonists, pyrimidine antagonists, purine antagonists, sugar-modified analogs, ribonucleotide reductase inhibitors -- Covalent DNA binding drugs -- Nitrogen mustards, aziridines, alkane sulfonates, nitrosoureas, platinum compounds, monoalkylating agents -- Noncovalent DNA binding drugs -- Antrhacyclines, mitoxantrone, dactinomycin, bleomycin, plicamycin -- Inhibitors of chromatin function -- Topoisomerase inhibitors, microtubule inhibitors -- Drugs affecting endocrine function -- Glucocorticoids, estrogens, antiestrogens, progestins, androgens, antiandrogens, LHRH (GnRH) agonists, aromatase inhibitors, adrenocortical suppressors -- Clinical cancer chemotherapy -- Choice of drugs for cancer chemotherapy -- Cancer treatment. (cont) New directions in cancer chemotherapy -- Anticancer drug development -- Biological treatments of cancer -- Potential targets for new anticancer drugs.
This is an up-to-date review of the pharmacology, mechanisms of action, development of resistance, and toxicity of cancer chemotherapeutic agents. A rationale for their clinical use, based on cancer cell biology, is given for each class of drugs.
9780195067385
CANCER -- CHEMOTHERAPY
RC 271.C5 .P73 1994
The anticancer drugs / William B. Pratt [and three others]. - Second edition. - New York : Oxford University Press, c1994 - viii, 352 pages : illustrations ; 26 cm.
Includes bibliographical references and index.
Principles of cancer chemotherapy -- Cancer problem -- Some milestones in the development of cancer chemotherapy -- Determinants of drug responsivveness -- Resistance to anticancer drugs -- Anticancer drugs -- Antimetabolites -- Folate antagonists, pyrimidine antagonists, purine antagonists, sugar-modified analogs, ribonucleotide reductase inhibitors -- Covalent DNA binding drugs -- Nitrogen mustards, aziridines, alkane sulfonates, nitrosoureas, platinum compounds, monoalkylating agents -- Noncovalent DNA binding drugs -- Antrhacyclines, mitoxantrone, dactinomycin, bleomycin, plicamycin -- Inhibitors of chromatin function -- Topoisomerase inhibitors, microtubule inhibitors -- Drugs affecting endocrine function -- Glucocorticoids, estrogens, antiestrogens, progestins, androgens, antiandrogens, LHRH (GnRH) agonists, aromatase inhibitors, adrenocortical suppressors -- Clinical cancer chemotherapy -- Choice of drugs for cancer chemotherapy -- Cancer treatment. (cont) New directions in cancer chemotherapy -- Anticancer drug development -- Biological treatments of cancer -- Potential targets for new anticancer drugs.
This is an up-to-date review of the pharmacology, mechanisms of action, development of resistance, and toxicity of cancer chemotherapeutic agents. A rationale for their clinical use, based on cancer cell biology, is given for each class of drugs.
9780195067385
CANCER -- CHEMOTHERAPY
RC 271.C5 .P73 1994